Treatment Options in CoViD19

Mallick, Umair

doi:10.1007/978-3-030-90065-6_5

Search citation statements

Order By: Relevance

Paper Sections

Select...

Recommendations1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the ability of pharmacists to initiate nirmatrelvir/ritonavir (Paxlovid) varies by province. 29,30 Relevant to results of this application, in April 2022, Quebec became the first Canadian jurisdiction to grant pharmacists the authority to prescribe nirmatrelvir/ritonavir (Paxlovid) to patients in a "test-to-treat" model, of which point-of-care antigen testing was a valid method of diagnosis 31 ; other provinces have since implemented a similar system. [32][33][34] The ability for pharmacists to test and treat in the same environment creates an opportunity for pharmacies to fill a gap by providing a connection between point-of-care testing and accessing appropriate therapies.…”

Section: Recommendationsmentioning

confidence: 99%